Monopar Therapeutics Inc. (MNPR) Dividend History

Monopar Therapeutics Inc. (MNPR) is a biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company aims to advance innovative drug candidates through clinical development with a focus on improving patient outcomes, often emphasizing repurposing existing drugs for new therapeutic applications.

1000 Skokie Blvd Suite 350, Wilmette, IL, 60091
Phone: (847) 388-0349
Website: https://www.monopartx.com

Dividend History

Monopar Therapeutics Inc. currently does not pay dividends

Company News

  • Monopar Therapeutics has in-licensed ALXN-1840, a late-stage drug candidate for Wilson disease, from Alexion, AstraZeneca Rare Disease. The company also has two novel radiopharma clinical trials active and enrolling patients with advanced solid cancers.

    GlobeNewswire Inc.
  • After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

    Zacks Investment Research
  • Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. Peraso posted a quarterly loss of $8.52 per share, versus analysts’ estimates for a loss of $3.76 per share. The company’s quarterly sales came in at $1.83 million versus expectations of $1.70 million. Peraso shares tumbled 23.3% to $1.32 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Ontrak, Inc. (NASDAQ: OTRK) shares climbed 197.8% to $0.5660 ahead of the company's presentation at the 36th Annual Roth Conference. Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) gained 97.3% to $20.99 after the company announced agreed to be acquired by AstraZeneca. Also, Leerink Partners downgraded the stock from Outperform to Market Perform but raised its price target from $17 to $21. SCWorx Corp. (NASDAQ: WORX) gained 74% to $3.22. Spire Global, Inc. (NYSE: SPIR) climbed 50.7% to $18.50 after announcing a collaboration with NVIDIA to advance AI-driven weather prediction. Enveric Biosciences, Inc (NASDAQ: ENVB) shares climbed 43.6% to $1.5801 after the company announced that it signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for pharmaceutical and non-pharmaceutical applications for the treatment of joint diseases. Zoomcar Holdings, Inc. (NASDAQ: ZCAR) rose 33.1% to $1.57 after the company announced that it partnered with EaseMyTrip to integrate its cars within the travel platform. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 32% to $1.51 after the company announced pre-clinical research showcasing the potential of HT-ALZ in Alzheimer's disease. Enliven Therapeutics, Inc. (NASDAQ: ELVN) gained 27.2% to $16.09. The company announced a $90 million private placement financing and provided pipeline updates. National CineMedia, Inc. (NASDAQ: NCMI) gained 25.5% to $5.30 after the company posted upbeat results for its fourth quarter and disclosed a new $100 million share repurchase program. The company said it sees first-quarter total revenue of $34.5 million to $35.5 million. Alignment Healthcare, Inc. (NASDAQ: ALHC) gained 17.7% to $5.50. Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose 15% to $43.63 ...

    Benzinga
  • Here's why penny stocks climb in value The post What Causes Penny Stocks to Climb in Price? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
  • Here are some of the biggest movers Tuesday in a session when banking names seemed to calm down after making wild swings over the past few weeks.

    MarketWatch
    Featured Companies: AAPL AFRM AMD CCL CIEN FCNCA KRE MKC MRVL MU OXY PVH RAIL WBA
Page data last updated 07/23/2025 07:42:59 UTC